Gregg Sherman, MD
Chief Medical Officer, NACE
Deborah Paschal, CRNP
Clinical Nurse Practitioner
Cardiothoracic Surgery Division
Penn-Presbyterian Medical Center
Kilbride Associates Healthcare Communications
San Francisco, CA
John M. Fontaine, MD, FACC
Professor of Medicine
Director Arrhythmia Services
Drexel University College of Medicine
Anekwe Onwuanyi, MD
Professor of Medicine
Morehouse School of Medicine
Medical Director, Heart Failure Program
Grady Health System
Laurence O. Watkins, MD, MPH, FACC
Former Director, Healthy Heart Center
Port St. Lucie, FL
Maria Galvao, NP
Center for Advanced Cardiac Therapy
Montefiore Medical Center
Robert L. Gillespie, MD, FACC, FASE,FASNC
Immediate Past Chairman of the Board
Association of Black Cardiologists, Inc.
Director of Nuclear Imaging
Sharp Rees-Stealy Medical Group
San Diego, CA
Elizabeth Ofili, MD
Professor of Medicine (Cardiology)
Senior Associate Dean, Clinical Research
Director, Clinical Research Center
Morehouse School of Medicine
Founder and Chairman of the Board, AccuHealth Technologies, Inc
||Clinical Challenges In Individualized Heart Failure Treatment
||Feb 01 2017
||Jan 31 2018
||Primary Care Providers
||1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.25 pharmacology hour(s)
| (Chrome not supported at this time)
This monograph reviews Heart failure (HF). Heart failure (HF) is a common, costly, and lethal condition. Nearly 6 million Americans have HF, a number that is expected to increase 25% by 2030. The management of HF is also a major contributor to healthcare costs. HF is currently the leading cause of hospitalization and rehospitalization among older individuals in the US, and Medicare reimbursements now depend in part on providers’ success in keeping patients out of the hospital. Finally, HF remains deadly; approximately 50% of people diagnosed with HF will die within 5 years. Although modest reductions in 30-day mortality have been reported by some studies, a high persistent mortality rate following hospitalization for HF indicates the need for greater adherence to evidence-based medical care and the development of novel agents and approaches to the management of HF.
After completing this program participants should be able to: 1. Recognize risk factors and use of biomarkers in diagnosis, prognosis and risk stratification of heart
2. Understand the racial/ethnic differences in pathophysiology and management strategies for heart
3. Demonstrate ability to recognize patients at high risk for early heart failure based on physical exam
and other clinical factors.
4. Implement evidence based strategies to decrease symptoms and improve quality of life for patients
with heart failure.
How To Obtain Your CME Certificate 1. Register for the course at www.naceonline.com.
2. View the content.
3. Complete and submit the post-test and evaluation.
4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME
5. Print your CME certificate.
National Association for Continuing Education & Association of Black Cardiologists, Inc.
|Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education(which includes 0.25 pharmacology hours).
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosures are provided below.
John M. Fontaine, MD, FACC, Faculty, has no relationships to disclose.
Anekwe Onwuanyi, MD, Faculty, serves a Speaker – Novartis Pharmaceuticals Corporation.
Laurence O. Watkins, MD, MPH, FACC, Faculty, has no relationships to disclose.
Maria Galvao, NP, Faculty, is a speaker for Merck; an advisor for Novartis and St. Jude; and a consultant for Boston Scientific.
Robert L. Gillespie, MD, FACC, FASE,FASNC, Faculty, is an investor for Eclypsa.
Elizabeth Ofili, MD, Faculty, receives grant/research support from the National Institute of Health. She is a consultant/advisory board member for Bristol-Meyers, Novartis Pharmaceuticals Corporation, Janssen Research and Development, Arbor Pharmaceuticals and Merck & Co.
Gregg Sherman, MD, Co-Course Director, has no relationships to disclose.
Deborah Paschal, CRNP, Co-Course Director, has no relationships to disclose.
Josh Kilbridge, Medical Writer, has no relationships to disclose.
Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
This activity is supported by is supported by an educational grants from Novartis Pharmaceuticals Corporation.